product design
405™LS微量盤清洗儀是BioTek公司第五代產品,以其優異可靠的性能著稱。405 LS可以通過其操作介面執行清洗,分注抽吸和維護等操作。對於那些習慣電腦操作或需要滿足21 CFR Part 11條款的操作,BioTek的LHC™軟體提供標準和21 CFR Part 11兼容版本。同時還可選配BioStack™來完成最多50塊微量盤的高通量自動化清洗操作。


Beyond standard dispense/aspirate protocols, the 405 LS automates liquid handling functions for many applications, and is ideal for integration into automated systems, controlled with LHC software.
  • Bead washing
  • Cell washing /media exchange

Fluorescence calibration curves for a 13-plex human metabolic hormone panel, using magnetic microspheres washed on the 405.
Fluorescence calibration curves for a 13-plex human metabolic hormone panel, using magnetic microspheres washed on the 405.

BioTek Field Applications Scientists (FAS) and Product Specialists provide unparalleled scientific support, assisting with experimental planning and assay optimization on BioTek’s instrumentation and software. Learn how they can help move your science forward… faster!


Intuitive onboard User Interface or LHC pc software


The 405 LS has a simple user interface for creation and execution of wash, dispense, aspirate and maintenance protocols within the extensive onboard software. For use under computer control, BioTek’s LHC™ Software is available in standard and 21 CFR Part 11 compliant versions.

Magnetic and polystyrene bead assays, conventional ELISAs


The 405 LS is ideal for many standard plate washing and dispensing protocols, but it also automates more complex operations like magnetic and polystyrene bead washing workflows – and it’s Luminex® xMap® approved. Bead washing is available for 96- and 384-well microplates.



Dual-Action™ manifold

405 TS

With its angled dispense tubes and adjustable flow rates, the 405 LS can process sensitive cell-based assays. The optional Dual-Action manifold and carrier offer X-Y-Z adjustment, perfect for optimizing plate positioning and residual removal for cell-based and other assays.



Live SARS-CoV-2 Research: Interlocking Pieces Working Together


When Dr. Robert Davey started researching Ebola virus drug development at the University of Texas Medical Branch (UTMB) at Galveston back in 2008, he had no idea just how keenly his work would prepare him to play a pivotal role in researching treatments for a very different global pandemic. In fact, a number of pieces fit together to support his current role in screening small molecule compounds that may be used in the fight against SARS-CoV-2, the novel coronavirus that causes COVID-19.




SILA Luminex xMAP Approval
下載文獻 獲取更多信息 產品詢價